Jerry Bagel

5.8k total citations · 1 hit paper
125 papers, 2.7k citations indexed

About

Jerry Bagel is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Jerry Bagel has authored 125 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Immunology, 56 papers in Dermatology and 29 papers in Pathology and Forensic Medicine. Recurrent topics in Jerry Bagel's work include Psoriasis: Treatment and Pathogenesis (101 papers), Dermatology and Skin Diseases (53 papers) and Autoimmune Bullous Skin Diseases (27 papers). Jerry Bagel is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (101 papers), Dermatology and Skin Diseases (53 papers) and Autoimmune Bullous Skin Diseases (27 papers). Jerry Bagel collaborates with scholars based in United States, Canada and Germany. Jerry Bagel's co-authors include Mark Lebwohl, Kim Papp, Abby S. Van Voorhees, Stephen K. Tyring, Bruce Strober, Andrew Blauvelt, Linda Stein Gold, Steven R. Feldman, David M. Pariser and John Koo and has published in prestigious journals such as New England Journal of Medicine, The American Journal of Medicine and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Jerry Bagel

112 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jerry Bagel United States	30	2.1k	1.5k	473	367	330	125	2.7k
Sascha Gerdes Germany	30	1.9k 0.9×	1.2k 0.8×	346 0.7×	315 0.9×	301 0.9×	116	2.5k
J.M. Carrascosa Spain	30	2.1k 1.0×	1.5k 1.0×	455 1.0×	383 1.0×	354 1.1×	211	3.0k
Peter van de Kerkhof Netherlands	21	2.3k 1.1×	1.5k 1.0×	473 1.0×	407 1.1×	417 1.3×	48	3.1k
Caitriona Ryan United States	28	2.2k 1.0×	1.3k 0.9×	498 1.1×	440 1.2×	404 1.2×	55	3.1k
Henry W. Lim United States	19	2.3k 1.1×	1.5k 1.0×	372 0.8×	367 1.0×	425 1.3×	34	3.0k
Ronald Vender Canada	26	1.8k 0.8×	1.4k 1.0×	388 0.8×	437 1.2×	306 0.9×	139	2.7k
Tiago Torres Portugal	31	1.5k 0.7×	1.4k 1.0×	488 1.0×	314 0.9×	377 1.1×	179	2.8k
Michel Le Maître France	24	2.0k 0.9×	1.2k 0.8×	703 1.5×	290 0.8×	182 0.6×	43	2.6k
Paul Klekotka United States	24	2.4k 1.1×	939 0.6×	311 0.7×	272 0.7×	416 1.3×	45	3.2k
Marieke M.B. Seyger Netherlands	29	1.7k 0.8×	1.3k 0.9×	396 0.8×	551 1.5×	335 1.0×	129	2.8k

Countries citing papers authored by Jerry Bagel

Since Specialization

Citations

This map shows the geographic impact of Jerry Bagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Bagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Bagel more than expected).

Fields of papers citing papers by Jerry Bagel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Bagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Bagel. The network helps show where Jerry Bagel may publish in the future.

Co-authorship network of co-authors of Jerry Bagel

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Bagel. A scholar is included among the top collaborators of Jerry Bagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Bagel. Jerry Bagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gebauer, Kurt, Lynda Spelman, Paul S. Yamauchi, et al.. (2024). Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. Journal of the American Academy of Dermatology. 91(1). 91–99. 6 indexed citations

Gold, Linda Stein, Andrew Blauvelt, Leon Kircik, et al.. (2024). Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms. SKIN The Journal of Cutaneous Medicine. 8(6). s430–s430. 1 indexed citations

Blauvelt, Andrew, et al.. (2024). Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatology and Therapy. 14(10). 2787–2804.

Korman, Neil J., Richard B. Warren, Jerry Bagel, et al.. (2024). Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal of Dermatological Treatment. 35(1). 2371045–2371045. 1 indexed citations

Korman, Neil J., Thierry Passeron, Yukari Okubo, et al.. (2024). Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8(6). s419–s419. 2 indexed citations

Blauvelt, Andrew, David M. Pariser, Stephen K. Tyring, et al.. (2023). Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. Journal of Dermatological Science. 109(1). 12–21. 11 indexed citations

Paller, Amy S., et al.. (2021). IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*. British Journal of Dermatology. 186(3). 496–507. 8 indexed citations

Blauvelt, Andrew, April W. Armstrong, Richard G. Langley, et al.. (2021). Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment. 33(4). 2317–2324. 21 indexed citations

Blauvelt, Andrew, Kenneth B. Gordon, Patricia Lee, et al.. (2021). Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. Journal of Dermatological Treatment. 33(4). 2085–2093. 12 indexed citations

10.

Merola, Joseph F., Lourdes M. Pérez-Chada, Michael Siegel, et al.. (2020). The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology. 34(9). 2051–2058. 6 indexed citations

11.

Bagel, Jerry, Andrew Blauvelt, John K Nia, et al.. (2020). Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology. 35(1). 135–142. 32 indexed citations

12.

Paller, Amy S., Marieke M.B. Seyger, Jerry Bagel, et al.. (2020). Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS ). British Journal of Dermatology. 183(2). 231–241. 69 indexed citations

13.

Silverberg, Jonathan I., Eric L. Simpson, Marius Ardeleanu, et al.. (2019). Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. British Journal of Dermatology. 181(1). 80–87. 44 indexed citations

14.

Bagel, Jerry, Bradley S. Stolshek, Girish Aras, et al.. (2018). Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.. PubMed. 17(10). 1078–1082. 5 indexed citations

15.

Green, Lawrence J., Francisco A. Kerdel, Fran Cook-Bolden, et al.. (2018). Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.. PubMed. 17(10). 1062–1069. 4 indexed citations

16.

Gold, Linda Stein, et al.. (2018). Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis. PubMed. 17(12). 1290–1296. 3 indexed citations

17.

Weiss, Jonathan, et al.. (2018). Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.. PubMed. 17(8). 855–861. 12 indexed citations

18.

Strober, Bruce, Jerry Bagel, Mark Lebwohl, et al.. (2017). Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.. PubMed. 16(8). 801–808. 44 indexed citations

19.

Duffin, Kristina Callis, Jerry Bagel, Michael Bukhalo, et al.. (2016). Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A). Journal of the European Academy of Dermatology and Venereology. 31(1). 107–113. 35 indexed citations

20.

Thaçi, Diamant, Gil Yosipovitch, Kim Papp, et al.. (2015). Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact